Loading clinical trials...

Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children

NCT07020052•Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

View on ClinicalTrials.gov

Summary

This study is a phase II single center exploratory clinical trial aimed at evaluating the efficacy and safety of temozolomide combined with anlotinib synchronous radiotherapy sequential triple therapy (temozolomide/anlotinib/PD-L1 inhibitor) for the maintenance treatment of diffuse midline gliomas (DMG) in children. The research plan includes 33 children with DMG aged 3-18 years, who have been pathologically diagnosed and have not received systematic treatment. The implementation will be divided into two stages: synchronous radiotherapy and chemotherapy stage (54Gy radiotherapy+oral temozolomide 75mg/m ²+sequential oral anlotinib) and maintenance treatment stage (increasing temozolomide dose+continuous use of anlotinib+intravenous injection of PD-L1 inhibitor according to body weight). Through multi mechanism synergy (radiotherapy sensitization, anti angiogenesis, and immune activation), the limitations of traditional treatment will be overcome. The primary endpoint is progression free survival (PFS), while secondary endpoints include objective response rate (ORR), 2-year overall survival rate (2y OS), quality of life, and safety (CTCAE 4.0 criteria). The innovation of the research lies in the first proposal of a "synchronous maintenance" staged mode, targeting the molecular characteristics of DMG (H3K27M mutation), combined with previous evidence at home and abroad (such as the median PFS of 10.2 months for anlotinib combined with synchronous radiotherapy), aiming to provide a new comprehensive treatment plan for this highly invasive tumor.

Eligibility

Age

3 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The standard for blood routine examination must meet the following criteria: (no blood transfusion within 14 days)
•1. Hb≥90g/L:
•2. ANC≥1.5\*10\^9/L;
•3. PLT≥80\*10\^9／L；
•2. Biochemical tests must meet the following standards
•1. BIL\<1.25 times the upper limit of normal (ULN);
•2. ALT and AST\<2.5\*ULN;
•3. Serum Cr ≤ ULN, endogenous creatinine clearance rate\>50ml/min (Cockcroft Gaut formula); 9. Sign a written informed consent form before conducting any experimental activities; 10. Researchers determine that they are able to comply with the research protocol; 11. Negative pregnancy test (for female patients with fertility) during screening; 12. Male patients with fertility and female patients with fertility and pregnancy risk must agree to use two contraceptive methods throughout the study period (at least one of which is considered an effective contraceptive method).
•Female patients who do not have fertility (i.e. meet at least one of the following criteria):
•* Have undergone hysterectomy and/or bilateral oophorectomy with documented records;
+4 more criteria

Exclusion Criteria

•1. Previously received anti-tumor treatment for diffuse midline glioma;
•2. Previous or concurrent malignant tumors (excluding malignant tumors that have been cured and have a cancer free survival of more than 5 years, such as basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid carcinoma);
•3. Uncontrolled clinical symptoms or diseases of the heart, such as: (1) NYHA grade II or above heart failure (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention in patients;
•4. Active infections that require treatment;
•5. People with congenital or acquired immune deficiency (such as HIV infected people), active hepatitis B (HBV-DNA ≥ 104 copies/ml or 2000IU/ml) or hepatitis C (hepatitis C antibody is positive, and HCV-RNA is higher than the detection limit of the analytical method);
•6. Known history of substance abuse, alcoholism, or drug use;
•7. According to the researcher's judgment, there may be other factors that could force the subject to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the subject's safety or the collection of trial data;
•8. Patients who the surgeon believes can undergo curative resection;
•9. Active pulmonary tuberculosis;
•10. Serious infections (including but not limited to hospitalization due to infection, bacteremia, or complications of severe pneumonia) that occurred within 4 weeks prior to the start of the study treatment.

Locations (1)

inyinhu Cancer Center, UnionMedical College Affiliated Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Key Dates

Start Date

July 10, 2025

Primary Completion Date

April 10, 2030

Completion Date

July 30, 2030

Last Updated

July 8, 2025

Enrollment

ESTIMATED participants

Conditions

Maintenance Treatment of Diffuse Midline Gliomas in Children

Interventions

temozolomide/anlotinib/pembrolizumab

DRUG

Contacts

lu wen, doctor

CONTACT

027-83262661 wenlu2808@126.com